Technical Analysis for KURA - Kura Oncology, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 17.24 | -2.49% | -0.44 |
Earnings due: May 8
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | -2.49% | |
Lower Bollinger Band Walk | Weakness | -2.49% | |
Below Lower BB | Weakness | -2.49% | |
Down 3 Days in a Row | Weakness | -2.49% | |
Down 4 Days in a Row | Weakness | -2.49% | |
Down 5 Days in a Row | Weakness | -2.49% | |
Lower Bollinger Band Touch | Weakness | -2.49% | |
Oversold Stochastic | Weakness | -2.49% | |
Lower Bollinger Band Walk | Weakness | -4.17% | |
Below Lower BB | Weakness | -4.17% |
Alert | Time |
---|---|
Down 3% | 18 minutes ago |
Down 2 % | about 1 hour ago |
60 Minute Opening Range Breakdown | about 2 hours ago |
2x Volume Pace | about 3 hours ago |
1.5x Volume Pace | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Kura Oncology, Inc. Description
Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Oncology Lymphoma Leukemia Signal Transduction Carcinoma Thyroid Oncogenes Blood Cancers Cell Signaling Protein Kinase Acute Leukemia Benzamides Peripheral T Cell Lymphoma Ras Subfamily
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 24.17 |
52 Week Low | 7.41 |
Average Volume | 927,768 |
200-Day Moving Average | 13.56 |
50-Day Moving Average | 20.80 |
20-Day Moving Average | 20.21 |
10-Day Moving Average | 19.45 |
Average True Range | 0.99 |
RSI (14) | 31.03 |
ADX | 20.53 |
+DI | 13.21 |
-DI | 29.21 |
Chandelier Exit (Long, 3 ATRs) | 19.85 |
Chandelier Exit (Short, 3 ATRs) | 20.49 |
Upper Bollinger Bands | 22.43 |
Lower Bollinger Band | 17.99 |
Percent B (%b) | -0.07 |
BandWidth | 21.96 |
MACD Line | -0.71 |
MACD Signal Line | -0.36 |
MACD Histogram | -0.3459 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 18.48 | ||||
Resistance 3 (R3) | 18.51 | 18.28 | 18.34 | ||
Resistance 2 (R2) | 18.28 | 18.08 | 18.26 | 18.30 | |
Resistance 1 (R1) | 17.98 | 17.95 | 17.87 | 17.95 | 18.25 |
Pivot Point | 17.75 | 17.75 | 17.69 | 17.73 | 17.75 |
Support 1 (S1) | 17.45 | 17.55 | 17.34 | 17.42 | 17.11 |
Support 2 (S2) | 17.22 | 17.42 | 17.20 | 17.06 | |
Support 3 (S3) | 16.92 | 17.22 | 17.02 | ||
Support 4 (S4) | 16.89 |